Matinas BioPharma Holdings (MTNB) Non Operating Investment Income (2019 - 2022)

Matinas BioPharma Holdings (MTNB) has reported Non Operating Investment Income for 4 consecutive years, with $1.8 million the latest figure, recorded in Q4 2022.

• In Q4 2022, Non Operating Investment Income rose 373929.79% year-over-year to $1.8 million; the TTM figure through Dec 2022 stood at $3.5 million (up 162.88% YoY), while the FY2023 annual figure was $484000.0, down 86.14% from the prior year.
• Non Operating Investment Income grew to $1.8 million in Q4 2022 per MTNB's latest filing, from $1.7 million in the prior quarter.
• Across five years, Non Operating Investment Income topped out at $1.8 million in Q4 2022 and bottomed at -$470.0 in Q4 2021.
• Historically, Non Operating Investment Income has averaged $1.1 million across 4 years, with a median of $1.2 million in 2020.
• Annual changes were most pronounced in 2021 — Non Operating Investment Income grew 23.78% — and 2022, when it jumped 373929.79%.
• Matinas BioPharma Holdings' Non Operating Investment Income stood at $1.0 million in 2019, then increased by 6.57% to $1.1 million in 2020, then slumped by 100.04% to -$470.0 in 2021, then surged by 373929.79% to $1.8 million in 2022.
• Business Quant data shows MTNB's Non Operating Investment Income at $1.8 million in Q4 2022, $1.7 million in Q1 2022, and -$470.0 in Q4 2021.